Recent studies highlight the demanding situations faced by life sciences corporations when generating knowledge-based insights that can aid decision-making in the product lifecycle. On average, it takes seven months to identify and integrate knowledge resources before groups can even begin to generate knowledge.
Using Komodo and Healthcare Map software programs, MoonLake was able to identify vital outcomes, which were presented in their R
“We are excited to help MoonLake’s efforts to advance clinical innovation and gain a deeper understanding of the patient adventure and unmet desires of others living with inflammatory diseases,” said Web Sun, president and co-founder of Komodo Health. As you plan to begin Phase 3 trials, we look forward to helping your groups use insights and analysis to benchmark the market, expand their commercialization strategy, and most importantly, help them commercialize their Nanobody® therapy, once approved, to patients who want it to the fullest. .
-Ends-
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that harnesses the potential of sonelokimab, an investigational new nanobody® for the treatment of inflammatory diseases, to revolutionize patient outcomes. Sonelokimab inhibits IL-17A and IL-17F by inhibiting IL-17A/A dimers. , IL-17A/F and IL-17F/F that cause inflammation. The company focuses on inflammatory diseases for which there is an unmet primary need, adding hidradenitis suppurativa and psoriatic arthritis, situations that millions of people internationalize and that require many steps. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. You can learn more at www. moonlaketx. com. The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.
About Komodo HealthKomodo Health is a generation enterprise platform that is creating the new in real-world insights and analytics by combining the industry’s most comprehensive view of patient encounters with enterprise software and device learning that connects the dots between individual patient journeys and fitness outcomes at scale. In the life sciences, payers, providers, and developers industries, Komodo consumers notice patient-centric insights at scale, combining clinical knowledge with complex algorithms and AI-powered software responses to inform decision-making, close gaps in care, reduce the burden of disease, and companies create a more cost-effective, value-based physical care system. For more information, visit Komodofitness. com.
About Psoriatic Arthritis
Psoriatic arthritis (Ps) is a chronic, progressive inflammatory arthritis related to psoriasis that primarily affects the peripheral joints. The clinical features of RP are diverse and involve pain, swelling, and stiffness of the joints, which can lead to reduced mobility and fatigue. PsA occurs in up to 30% of psoriasis patients, most often in people between the ages of 30 and 60. The burden of RP symptoms can have a significant negative effect on patients’ quality of life. Although the precise mechanism of the disease is not fully understood, knowledge recommends that activation of the IL-17 pathway plays a vital role in the pathophysiology of the disease.
About Nanobodies®
Nanobodies® are a new generation of targeted therapies derived from antibodies. They consist of one or more domain names based on the small variable antigen-binding regions of heavy chain antibodies (HHV) only. Classical® antibodies, coupled with their small size, advanced tissue penetration, resistance to temperature changes, ease of fabrication, and the ability to be remodeled into multivalent healing molecules with adapted target combinations.
The terms Nanobody® and Nanobodies® are from Ablynx, a Sanofi company.
Cautionary Note Regarding Forward-Looking Statements
Forward-looking statements are based on existing expectations and assumptions that, while considered moderate through MoonLake and its management, as applicable, are inherently uncertain. New dangers and uncertainties may arise from time to time, and it is unimaginable that they are waiting for all the dangers and uncertainties. Actual effects may also differ materially from those expected in those forward-looking statements as a result of various dangers and uncertainties, including, but not limited to, dangers and uncertainties related to MoonLake’s business at times and limited operating history. , the difficulty of enrolling patients in clinical trials, and the use of third parties to conduct and assist in their clinical trials. and other perils described or incorporated by reference in MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2023, and upcoming filings with the Securities and Exchange Commission.
Nothing in this press release should be construed as a sign that the forward-looking statements set forth herein will be known or that any of the expected effects of such forward-looking statements will be realized. You deserve not to place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date they were made and are qualified in their entirety by reference to the warnings contained in this press release. MoonLake does not take any legal responsibility to publicly update or revise any forward-looking statements to reflect any forward-looking statements or the events, situations or cases on which they are based.
medios:media@komodohealth. com Contacts
MoonLake Immunotherapy MediaPatricia Marques de Sousamedia@moonlaketx. com
Attached